CompletedNCT06419582
BHV-7000 study for acute mania in bipolarity
About this title
Read the official source — NCT06419582Researchers compared BHV-7000 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Medication studyAges 18–75United States
Understand this study
What did researchers investigate?
Researchers compared BHV-7000 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- Bentonville and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: May 28, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 274
- Sponsor
- Biohaven Therapeutics Ltd.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT06419582
- Official title
Show the full official title
A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bentonville · Little Rock · Rogers
26 more locations
- Anaheim
- Bellflower
- Culver City
- Garden Grove
- Lemon Grove
- Orange
- Riverside
- Torrance
- Hollywood
- Miami
- Miami Lakes
- West Palm Beach
- Atlanta
- Decatur
- Savannah
- Chicago
- Gaithersburg
- Flowood
- St Louis
- Marlton
- Staten Island
- Dayton
- North Canton
- Austin
- DeSoto
- Richardson
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared BHV-7000 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who is behind this study?
The study sponsor is Biohaven Therapeutics Ltd.
Did this study involve medication?
Yes. The study involved medication, including BHV-7000 and Placebo.
Who was this study for?
Listed age limits: 18 years to 75 years.
